Rituximab biosimilar - Sandoz

Drug Profile

Rituximab biosimilar - Sandoz

Alternative Names: GP 2013; Rixathon; Riximyo

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Sandoz
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Microscopic polyangiitis; Rheumatoid arthritis; Wegener's granulomatosis

Most Recent Events

  • 25 Apr 2017 Committee for Medicinal Products for Human Use (CHMP) recommends approval of rituximab biosimilar for Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Follicular lymphoma, Microscopic polyangiitis, Rheumatoid arthritis and Wegener's granulomatosis in the European Union
  • 28 Feb 2017 University of Leeds plans a phase II trial for Systemic lupus erythematosus arthritis in United Kingdom (NCT03054259)
  • 01 Nov 2016 Sandoz completes a phase-II clinical trial in Rheumatoid arthritis (Treatment-experienced) in Argentina, Austria, Belgium, Brazil, Estonia, France, Germany, Hungary, India, Italy, Poland, Romania ,Spain, Turkey, USA and United Kingdom (EudraCT2010-021184-32; NCT01274182)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top